Ruth Campbell - Academia.edu (original) (raw)
Uploads
Papers by Ruth Campbell
Kidney International, 2003
Proteinuria is a major predictor of decline in renal nist treatment in human chronic nephropathie... more Proteinuria is a major predictor of decline in renal nist treatment in human chronic nephropathies. function in patients with non-diabetic, proteinuric renal Background. Proteinuria predicts renal disease progression, disease. The Modification of Renal Disease (MDRD) and its reduction by angiotensin-converting enzyme inhibitors [1] and Ramipril Efficacy in Nephropathy (REIN) [2]
Journal of the American Society of Nephrology, 2002
The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alo... more The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alone, there were 372,000 patients requiring renal replacement therapy in the year 2000 and is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. These increases represent a significant burden to countries worldwide; not only due to the financial costs of providing ESRD care, but also because of lost productivity and significant morbidity and mortality for the affected patients.
Pharmaceuticals, 2010
We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with i... more We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to a systolic/diastolic blood pressure <120/80 mmHg. Blood pressure, 24-hour urinary protein excretion, and creatinine clearance were measured prior to, after two months of combined therapy, and after a 2-month withdrawal period of spironolactone. While systolic and diastolic blood pressure decreased significantly after spironolactone therapy, proteinuria did not improve. Serum potassium increased significantly as well, with three patients requiring resin-binding therapy. Thus, spironolactone seems to have no additional antiproteinuric effects over ACE inhibitor therapy in patients with IMN and nephrotic syndrome and carries the risk of significant hyperkalemia.
Kidney International, 2003
Proteinuria is a major predictor of decline in renal nist treatment in human chronic nephropathie... more Proteinuria is a major predictor of decline in renal nist treatment in human chronic nephropathies. function in patients with non-diabetic, proteinuric renal Background. Proteinuria predicts renal disease progression, disease. The Modification of Renal Disease (MDRD) and its reduction by angiotensin-converting enzyme inhibitors [1] and Ramipril Efficacy in Nephropathy (REIN) [2]
Journal of the American Society of Nephrology, 2002
The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alo... more The incidence of end-stage renal disease (ESRD) is increasing worldwide. In the United States alone, there were 372,000 patients requiring renal replacement therapy in the year 2000 and is expected to rise to 650,000 by the year 2010. The trends in Europe and Japan are forecasted to follow a similar path. These increases represent a significant burden to countries worldwide; not only due to the financial costs of providing ESRD care, but also because of lost productivity and significant morbidity and mortality for the affected patients.
Pharmaceuticals, 2010
We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with i... more We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to a systolic/diastolic blood pressure <120/80 mmHg. Blood pressure, 24-hour urinary protein excretion, and creatinine clearance were measured prior to, after two months of combined therapy, and after a 2-month withdrawal period of spironolactone. While systolic and diastolic blood pressure decreased significantly after spironolactone therapy, proteinuria did not improve. Serum potassium increased significantly as well, with three patients requiring resin-binding therapy. Thus, spironolactone seems to have no additional antiproteinuric effects over ACE inhibitor therapy in patients with IMN and nephrotic syndrome and carries the risk of significant hyperkalemia.